CHUGAI PHARMACEUTICAL CO., LTD.

Emicizumab (Hemlibra) is a bi-specific antibody for hemophilia A, under development for mild to moderate hemophilia A and Von Willebrand Disease. Chugai Pharmaceutical, a subsidiary of Roche, specializes in biotechnological research and drug manufacturing, offering products for various therapeutic areas.

Chugai Pharmaceutical filed for an additional indication with MHLW for Vabysmo, targeting angioid streaks with neovascularization, receiving orphan drug designation. Based on a Japanese phase III study, Vabysmo demonstrated vision improvement, aiming to provide a new treatment option for this rare disease.

Roche expands its digital pathology open environment with 20+ AI algorithms from 8 new collaborators, aiming to enhance cancer diagnostics and personalized healthcare.